Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Egypt / NCT07003451
Starting soon Observational

Novel Biomarkers in Assessment of Interstitial Lung Disease Associated With Rheumatoid Arthritis Patients

NCT07003451 · tracked via the Priya Life Science Egypt tracker
Sponsor
Assiut University
Phase
Observational
Started
2025-10-01
Last updated
2025-08-28

Condition(s) studied

Rheumatoid ArthritisInterstitial Lung Disease

Investigational drug(s) / intervention(s)

Calprotectin Level

Calprotectin Level: Measurement of calprotectin level to presence and severity of ILD asessed via Warrick's score

Study summary

\- Assess Krebs von den Lungen-6 (KL-6) and Calprotectin as novel biomarkers for diagnosis of ILD among Rheumatoid arthritis patients

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Confirmed diagnosis of Rheumatoid arthritis, age \> 18 years. Exclusion Criteria: * Patients who refuse to participate in the study, * Patients with evidence of worsening or exacerbation of RA over the previous 6 months, * concomitant diagnosis of an active neoplasia, or * patients who had previously received radiotherapy, * End organ failure.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Assiut University hospital Asyut Egypt

More Assiut University trials in Egypt

Correlation Between Vaginal Laxity and Delivery Mode Recruiting
The Diagnostic Utility of T Immunoglobulin G and T Immunoglobulin M Biomarkers in Patients With Systemic Lupus Erythematosus Disease : Associations With Disease Activity and Damage Starting soon
Donor Site Morbidity After Free Vascularized Fibular Graft Recruiting
Expression of Tim-3 on Neutrophils in Ankylosing Spondylitis Starting soon
Lap Adhesiolysis in Intestinal Obstruction Recruiting

Other trials for the same condition

CT Quantitative Assessment of Interstitial Lung Disease Recruiting
Baricitinib Effects on Procoagulant State in Rheumatoid Arthritis Starting soon
Effect of Some Drugs on Rheumatoid Arithritis Activity Recruiting
Nerve Conduction Study for Assessment of Peripheral Neuropathy in Rheumatoid Arthritis Patients on the Janus Kinase Inhibitor Baricitinib Recruiting
Effect of Roflumilast and Desloratadine as Add-On Therapy in Patients With Rheumatoid Arthritis Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07003451 on ClinicalTrials.gov ↗ ← All trials in Egypt